The company finished the March quarter with $21 million in the bank.
Showing 25 of 3001
The new Pronto range of dual action products is set to go on sale in the second half of this year.
The breast cancer and colorectal tests will provide healthcare providers and their patients with risk assessments of the patient developing breast cancer.
The retail entitlement offer had a take-up rate of about 54.7% for acceptances of entitlements and applications for additional shares by eligible retail shareholders.
The company remains in voluntary suspension to facilitate completion of its recapitalisation plan.
The company plans to begin recruitment for its upcoming dose expansion cohort immediately.
The company told Proactive Investors in February that it remained on track for record revenues in financial year 2019, targeting profitability in financial year 2020.
The company’s Onco-PDO cancer screening service supports personalised clinical decisions for patients.
The company expects the licenced brand will achieve sales with Chemist Warehouse of around $500,000.
The company has today commenced the retail component of its $77.9 million capital raising.
Dr. Lesley Russell brings extensive pharmaceutical experience to the board including a number of cancer therapy collaborations with Teva Pharmaceuticals.
The company has a portfolio of medical products in market and final stages of testing.
The company will showcase its Pronto technology at the American Academy of Sleep Medicine Meeting in San Antonio, Texas, in June.
Hong Kong investor Sun Bright Holdings is contributing up to $18 million for cancer vaccine and immunotherapies development
The trading halt will remain in place until an announcement is made or until the beginning of trade on April 12, 2019.
The acquisition will give the company access to China-based retail customers through e-commerce and online platforms as well as a network of retail stores.
The financial impact is expected to be positive with the progressive delivery of a minimum of $20 million in orders over a three-year period contemplated.
The medical technology company specialises in the development and marketing of premium non-invasive cardiovascular and pulmonary medical devices.
The dealer licence which was previously under the narcotic control regulations of the controlled drugs and substances act, has now been changed to the recently enacted cannabis act and cannabis regulations.
New Zealand listed shares in Synlait opened 12% lower this morning signalling a disappointing result.
Clostridium difficile remains a major medical problem, causing an estimated economic burden of more than US$10 billion globally with 28,000 deaths per year in the US alone.
The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
The company is developing a pipeline of products to treat inflammation and fibrosis.
The agreement underpins the company’s strategy to develop and launch its own branded products by providing higher production volumes and cash flows through ingredient sales.
The GFS solution provides storage and distribution capabilities to automate and streamline the Polaris facility’s nutrient lifecycle planning.